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Abstract. The present study established systems to predict the 
chemo-sensitivity of muscle invasive bladder cancer (MIBC) 
for neoadjuvant chemotherapy (NAC) with methotrexate, 
vinblastine, doxorubicin plus cisplatin (M-VAC) and carbo-
platin plus gemcitabine (CaG) by analyzing microarray data. 
The primary aim of the study was to investigate whether the 
clinical response would increase by combining these predic-
tion systems. Treatment of each MIBC case was allocated 
into M-VAC NAC, CaG NAC, surgery, or radiation therapy 
groups by their prediction score (PS), which was calculated 
using the designed chemo-sensitivity prediction system. The 
therapeutic effect of the present study was compared with the 
results of historical controls (n=76 patients) whose treatments 
were not allocated using the chemo-sensitivity prediction 
system. In addition, the overall survival between the predicted 
to be responder (positive PS) group and predicted to be 
non-responder (negative PS) group was investigated in the 
present study. Of the 33 patients with MIBC, 25 cases were 
positive PS and 8 were negative PS. Among the 25 positive PS 
cases, 7 were allocated to receive M-VAC NAC and 18 were 
allocated to receive CaG NAC according to the results of the 
prediction systems. Of the 8 negative PS cases, 3 received 
CaG NAC, 1 received surgery without NAC and 4 received 
radiation therapy. The total clinical response to NAC was 
88.0% (22/25), which was significantly increased compared 
with the historical controls [56.6% (43/76) P=0.0041]. Overall 
survival of the positive PS group in the study was significantly 
increased compared with the negative PS group (P=0.027). 
In conclusion, the combination of the two prediction systems 
may increase the treatment efficacy for patients with MIBC 
by proposing the optimal NAC regimen. In addition, the posi-
tive PS group would have a better prognosis compared with 
the negative PS group. These results suggest that the two 
prediction systems may lead to the achievement of ‘precision 
medicine’.
Introduction
Prognosis of muscle invasive bladder cancer (MIBC) has 
not significantly improved in the past several decades (1). 
Neoadjuvant chemotherapy (NAC) is well understood as an 
applicable strategy for MIBC. However, some patients who 
undergo NAC do not receive any benefit, and others are not 
candidates for surgery because of disease progression.
We have been predicting the effectiveness of NAC for 
MIBC by using microarray analyses. The prediction systems 
were established a combination of methotrexate, vinblastine, 
doxorubicin plus cisplatin (M-VAC) in 2005 and carboplatin 
plus gemcitabine (CaG) in 2011, respectively (2,3). In our 
prior retrospective study, we reported that M-VAC and CaG 
prediction systems showed the result of nearly 90% accu-
racy predicting the chemo-sensitivity for M-VAC and CaG, 
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respectively (2-4). Moreover, to investigate the clinical 
implications of these two systems that predict the response to 
M-VAC and CaG for NAC, we simulated the clinical response 
of the CaG-treated 37 patients to M-VAC therapy using our 
M-VAC prediction system; conversely, we also applied the 
CaG prediction system indicated above to the M-VAC treated 
39 patients who had been previously reported (2-4). As a result 
of considering the positive and negative predictive accuracies 
of the prediction systems for responsiveness to M-VAC and 
CaG, 80.1% of the 76 patients who received M-VAC or CaG 
prediction system were predicted as responders for at least 
M-VAC or CaG regimen using the combination of the two 
systems (4).
Based on these results, the primary aim of this research is to 
investigate whether by combining M-VAC and CaG prediction 
systems NAC performance to MIBC will be improved more 
than historical control groups who have not been allocated 
NAC regimen according to the results of prediction systems. 
The secondary aim was to compare with overall survival 
between predicted to be responder group and predicted to be 
non-responder group in this prospective study.
Patients and methods
Patients. The Ethics Committee of Iwate Medical University 
(Iwate, Japan) approved this clinical trial prior to patient 
recruited and is registered with the UMIN CTR as 
UMIN000019902. Bladder cancer tissue samples, which were 
confirmed as urothelial carcinoma, from punch biopsies and 
the corresponding clinical information were obtained from 
Iwate Medical University after each patient provided written 
informed consent. Clinical stage was judged according to 
the Tumor‑Node‑Metastasis classification. We enrolled only 
patients who had no lymph node metastasis as determined by 
computed tomography (CT) from the chest to the pelvis as well 
as magnetic resonance imaging (MRI) of the abdomen and 
pelvis at clinical stages T2aN0M0 to T4aN0M0 (Stage II-III); 
patients were expected to undergo radical cystectomy without 
prior radiation therapy. None of the participants had any serious 
abnormality in renal, hepatic, or hematologic function or had 
an Eastern Cooperative Oncology Group performance status 
judged to be ≤2. As historical controls, previous patients who 
received either the M-VAC or CaG regimen were matched for 
both clinical data and the prediction system used. Hence, the 
patient characteristics and results of our previous studies were 
used. Using the predicting systems for the response to M-VAC 
and CaG, we obtained 39 and 37 cases, respectively. Eighteen 
of 39 M-VAC cases and 18 of 37 CaG cases served as learning 
cases to establish the prediction system; the remaining 21 and 
19 cases, respectively, were used as test cases to verify the 
prediction scoring system based on expression data.
From preservation of tissue samples, RNA extraction and 
reverse transcription‑quantitative polymerase chain reaction 
for the calculation of the prediction score (PS). Several cancer 
tissue samples were obtained from each patient at the time 
of biopsy before NAC. These samples were immediately 
embedded in TissueTek OCT compound (Sakura, Tokyo, 
Japan), frozen and stored at ‑80˚C. The frozen tissues were sliced 
into 8-µm sections using a cryostat (Sakura) and were then 
stained with H&E for histologic examination. Bladder cancer 
cells were selectively enriched for our experiments using the 
EZ-cut system with a pulsed UV narrow beam focus laser (SL 
microtest GmbH, Germany) according to the manufacturer's 
protocols. Total RNA extraction were performed by using 
RNeasy Micro Kits (Qiagen Inc., Valencia, CA, USA) as 
previously described (5,6). We extracted approximately 9 µl of 
total RNA from each sample. Seven of the 9 µl were used for 
M-VAC analysis, and the remainder was used for CaG analysis. 
The M-VAC group was directly analyzed by RT-qPCR by 
using oligo-dT primer and SuperScript II reverse transcriptase 
(Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA). 
In the CaG group; we followed the protocol previously 
described in the Affymetrix GeneChip 3'IVT Express Kit 
User Manual protocol (Affymetrix, Santa Clara, CA, USA) 
the after that performed RT-qPCR (3). In the RT-qPCR of 
CaG group, we used the random hexamer and SuperScript II 
reverse transcriptase (Invitrogen; Thermo Fisher Scientific). 
For M-VAC analysis, expression of 14 predictive genes and 
one endogenous control gene was measured by quantitative 
RT-qPCR using the Format 16 (cat. no. 4346798) of Custom 
TaqMan® Array Cards (Invitrogen; Thermo Fisher Scientific) 
on an ABI Prism 7900 Sequence Detection system (Applied 
Biosystems Life Technologies, Foster City, CA, USA) according 
to the supplier's protocol. The PCR cycling parameters of 
M‑VAC (40 cycles) were as follows: Predenaturation (95˚C, 
10 min), denaturation (95˚C, 15 sec), annealing and extension 
(60˚C, 60 sec). Moreover, relative expression ratios of each 
sample were calculated as described previously (2,3,7). The 
expression of the 12 predictive genes for CaG and 1 endogenous 
control gene was measured by RT-qPCR using TaqMan Gene 
Expression Assay products on a Light Cycler 480 system 
(Roche Applied Science, Basel, Switzerland) as described 
previously (3). The PCR cycling parameters of CaG (45 cycles) 
were as follows: Predenaturation (95˚C, 10 min), denaturation 
(95˚C, 10 sec), annealing and extension (55˚C, 50 sec). The 
M‑VAC and CaG sequences of the primers and fluorogenic 
TaqMan MGB probes are shown in Table I (2,3). The 
normalized gene expression values were log-transformed (on 
a base 2 scale). Moreover, to normalize the expression of each 
gene, we selected as internal controls chaperonin-containing 
TCP1, subunit 6A (CCT6A). To keep reproducibility, the 
expression levels of M-VAC were calculated by means of 2-ΔΔCq 
method (8) and were normalized to that of using our previous 
control from bladder samples and the expression levels of CaG 
were calculated by means of standard curve method and our 
previous control from bladder samples were used as standard 
samples respectively. Based on the results of each relative 
expression ratio, we calculated prediction score (PS) of M-VAC 
and CaG according to previously described procedures (2,3,9). 
PS values ranged from -100 to 100; positive PS which ranged 
from 0 to100 is defined as predicted to be responder. On the 
other hand, negative PS which ranged from ‑100 to 0 is defined 
as predicted to be non-responder.
Allocated treatments. Based on the results of the PS and patient 
wishes, patients were allocated to receive one of the four treat-
ments: M-VAC, CaG, surgery, or radiation therapy (Fig. 1). 
Patients who were positive PS for M-VAC or CaG were given 
two or three 28-day cycles of M-VAC or 21-day cycles of CaG 
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Table I. List of primer sets and TaqMan probes of M-VAC and CaG Predictive genes.
Public ID  Symbol  Forward primer (5'-3') Reverse primer (5'-3') TaqMan probe (5'-3')
A, Internal control
AF385084  CCT6A  CTCCTGCACT GACATTCCAGCTCGC FAM-CAACATTCTCT
  GTGATTGCCA ATGATC TGGTTGATG-MGB
B, M-VAC Predictive genes     
L19067 RELA TGGCTGAAGGAAACAGTGCA AAACCCCTTCTGGA FAM-CAGCACTGGCTC
   TCCTGG TC-MGB
BU625507 SLC16A3 TGGATCTGCGGTGAAGCC CCCCTGGTGAGGATG FAM-AGCCGCAAGGTT
   CCT AC-MGB
J04088 TOP2A AAAAGCCTGATCCTGCCAAA CATCAGAAGTGGATG FAM-CCAAGAATCGCC
   GCTTCC GCAAA-MGB
AK025288   CCTCCGTCACACACACGAGT ACTGGGAACAAGAG FAM-ACATAGGATAGAT
   CCACATG ATGTGTATGTGA-MGB
BC006992 PIR51 CGCCTTGGCTTGTCCAGAT GGTGCTAGTGGCATT FAM-AGCACGAGTTAA
   TGGATG ACCT-MGB
X80497 PHKA2 ATCCTCCTGGCGGCAGTAG GCACAGACAGACTG FAM-TGACAAGGGCCA
   CATCCTG CCTC-MGB
BX094005   GGGACACAGGAGATTGGCAG GGTGGAGGGAGGGC FAM-CCAACACAGCTA
   TAGAGA GCC-MGB
NM_005461 MAFB GTCCTGCATCAGAAACGAGCT TGCGGCAGGTTTGA FAM-TGGTTTTTACAGA
   TTTCA TTCAAC-MGB
BC062996 DBI ATGGTGGGAATTCGGGAAA GAGCCGTATGGTGA FAM-CCAGTTAAACCA
   GCAGC GCTACT-MGB
L41143 TCTA CCATCTGGCTGCCTTTGCT GCTGCAATTCCAGG FAM-AAGCCATCTTTGT
   GCC GGTAGAG-MGB
AK025736 HMGCS1 CAATGAAAATAAGGTATGACC TCCTACTTCAGACCT FAM-TTACCTAGTCTGA
  CAAGTT TGAAGTGGA CTAGAAGTA-MGB
AL136794 RACGAP1 GGAAGATTGTCAATATTTTGT TTTCAGCATCCAAAG FAM-AAGCTACAGTCA
  GGTAAGA TGCAAAG TTTTT-MGB
BM677885 RASL11B TGGCAATGACGTTGGGTTG ATTTCAGCCACCCTT FAM-CTAGGCCTGGCT
   AGGCA GAGTT-MGB
BU622526 C14orf142 TGTTATAAAGAGTACATGTCA AATTTTCACTACTTG FAM-AGGCAGTAACAT
  CGGTTCA TTCATGTCAGTTCT TTCA-MGB
C, CaG Predictive genes   
AL137335  IPO7  TTGTGGTGCACTCACCTCTGA CAATGAAATACCACT FAM-AGTGACTTGAAT
   AACCCCTTTTT TCGG-MGB
BC043571  LOC613266 CCTCCAAGAGTGTTCGATTT CCTGCGTTCAGACTA FAM-CATTGTGCAATTT
  CAA CTTGAGTAAGA C-MGB
BF508662  SPRY1 CTTTTGGCCCCTTGGATAGTT AGGCAAGGAAAACA FAM-ACAGCTGAGTAA
   CAGAAGAGA TTCT-MGB
AI884890  OSBPL11 AGGTTCTTCTCTGTTTACCCT CAATCAGGAAGCAG FAM-CCCAGAATGGAG
  AAATCC GTCACTCA TCATT-MGB
NM_016220  ZNF107 TGCTCTTCATTCCTATTGTATT CATAAATAATACCGA FAM-CATGCATCAAAG
  CACAT CCTAACAGAAATGAT ATATGAGA-MGB
AI025829   TGTTTTTCAGTTGCTGCACTT GCATATTCCAGCAAT FAM-TTTAATCTTGCTC
  TTT TACCTTTGA AGTCCC-MGB
AF090916   TGGCAATATCCTTTTCTCTGA GGCCTTGGTTGCCCA FAM-AAAGTTAGGCTG
  TTTT AA AGTGCAGT-MGB
N63709  LIN7C CCTCTGCCAACAATC CCATACCTGGAA FAM-ATTGTTGTCTAAA
  TGGTTTT TAACCTTTGAAGA GTTTGCTAGTAG-MGB
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as previously described, respectively (2-4). They underwent 
surgery consisting of cystectomy or trans-urethral resec-
tion of the bladder tumor (TUR-BT), radiation therapy, or 
supportive care according to the NAC outcome and perfor-
mance status of each patient. Patients allocated to surgery 
underwent radical cystectomy and ileal conduit formation, 
cutaneous ureterostomy, or complete TUR-BT performed 
within 40 days post-biopsy or post-chemotherapy. Radical 
cystectomy included internal, external iliac, and obturator 
pelvic lymph node dissection. Radiotherapy was administered 
as intensity-modulated radiation therapy, aiming at delivering 
approximately 66 Gy to the bladder and pelvic nodes.
Follow‑up. Post-primary and/or secondary treatment follow-up 
included evaluation of blood count, blood chemistry (particu-
larly for kidney function), urinary cytology, and CT scans of 
the chest, abdomen, and pelvis every three months for the first 
two years and at six-month intervals for the next three years 
until recurrence or according to clinician discretion. Patients 
who relapsed received evidence-based treatments or best 
supportive care according to clinician assessment.
Statistical analysis. We calculated positive predictive accura-
cies and negative predictive accuracies for cases with selective 
NAC in our study. The results of positive predictive accura-
cies of M-VAC (PPAM-VAC), negative predictive accuracies of 
M-VAC (NPAM-VAC) and positive predictive accuracies of CaG 
(PPACaG), negative predictive accuracies of CaG (NPACaG) ther-
apies were calculated as a function of the patients who received 
selective NAC according to the results of the respective predic-
tion systems. In terms of clinical efficacy, to decrease selection 
bias as much as possible, we compared the intention-to-treat 
proportion of patients achieving significant tumor shrinkage 
who received each of the two regimens with that of historical 
controls (2-4). In the NAC group, we categorized patients 
into two groups according to NAC response: ‘Responders’ 
who achieved significant tumor shrinkage (>60%), and 
‘non‑responders’ (≤60%) by the MRI or CT images. Based 
on their response and prediction results, patients were each 
evaluated as either ‘accurate’ or ‘inaccurate’ to the predic-
tion system. Moreover, we did not only compare the overall 
survivals between the positive PS group and negative PS group 
but this prospective and historical control, respectively. Data 
Table I. Continued.
Public ID  Symbol Forward primer (5'-3') Reverse primer (5'-3') TaqMan probe (5'-3')
AL043021  WDR90 GCCTGGAGCAAGCT CAAAAGGGCAAC FAM-TTTGGCGCCCTG
  GTTGTAA AGGTATGAAAG TGAA-MGB 
NM_002555 SLC22A18 TTTGGCGTCCCCGTC GGACCAGGAGGA FAM-CACGTGCAGGTT
  TT CAAGGGTATT GCTA-MGB
NM_018129 PNPO ATCACACCTGCCTGA CCTGACGGACTG FAM-TGGGCTGTCACT
  GAAGGA GGAATAAAAA AGGA-MGB
NM_005207 CRKL TTGAGGCCATGGCG GCAGCTAAGCCA FAM-CTGCATGTTTGCT
  AGAT CTGCTTTGT GTTC-MGB
The probes contain a 6‑carboxy‑FAM label at the 5'end of the gene and a MGB and nonfluorescent quencher at the 3'end. FAM, fluorescein 
phosphoramidite; MGB, minor groove binder.
Figure 1. Flow chart of methods. M-VAC, methotrexate, vinblastine, doxorubicin plus cisplatin; CaG, carboplatin plus gemcitabine; PCR, polymerase chain 
reaction; PS, prediction score.
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were analyzed using JMP® 10 (SAS Institute Inc., Cary, NC, 
USA) statistical software. The association between this study 
and the historical control study were analyzed using t-tests 
and χ2 tests. Kaplan-Meier survival curves were plotted, and 
the significance of differences between survival curves was 
determined using the log-rank test. P<0.05 was considered to 
indicate a statistically significant difference.
Results
Patient characteristics. From March 2011 to July 2013, 
33 MIBC patients (10 women and 23 men; median age, 
70 years; age range, 46-78 years) were enrolled in our 
study. Patient characteristics are listed in Table II including 
76 historical control cases (2-4). Among 76 cases, 39 patients 
in the M-VAC group (nine women and 30 men; median age, 66; 
range, 53-77 years) were enrolled into study between July 2002 
and August 2004 and 37 patients in the CaG group (six women 
and 31 men; median age, 67; range, 52-78 years) were enrolled 
between May 2008 and April 2010. No significant differences 
were detected in age, sex and clinical T(cT) stage between the 
present cohort of patients and those of the historical control 
group (Table II).
Allocated treatment. PS analysis of all 33 cases was completed 
successfully. The distribution of cases according to predicted 
responses to M-VAC or CaG therapy is summarized in a 
scatter plot of the PSs in Fig. 2. No correlation was detected 
between M-VAC and CaG PSs (Pearson's correlation coef-
ficient; r=0.063). Among the 33 patients analyzed by each 
prediction system, nine were positive PS to both M-VAC and 
CaG therapies (upper right in Fig. 2), six were positive PS to 
only M-VAC therapy (lower right in Fig. 2), 10 were positive 
PS to only CaG therapy (upper left in Fig. 2), and eight were 
negative PS to both therapies (lower left in Fig. 2). Therefore, 
in all 33 MIBC patients, 25 cases were positive PS and eight 
were negative PS (Fig. 1). Among 25 responder cases, seven 
were allocated to M-VAC, 21 to CaG, one to surgery and four 
to radiation according to PSs and patient wishes (Fig. 1). Five 
patients who received surgery or radiation therapy declined 
NAC (Fig. 1).
The accuracy of prediction systems for clinical response to 
NAC. Twenty-eight of the 33 patients received NAC in our 
prospective study (Fig. 1). Among of 15 patients who were 
positive PS in M-VAC scoring system, 7 received M-VAC 
NAC, 6 out of 7 patients clinically responded. No patient 
with a negative PS received M-VAC. Therefore, PPAM-VAC and 
NPAM-VAC were 85.7% (6/7) and no data (no cases). In contrast, 
among of the 19 cases showing positive PS in CaG scoring 
system, 18 cases received CaG NAC, 16 out of 18 patients 
clinically responded. Three patients showing negative PS in 
CaG scoring system received CaG NAC (Fig. 1). Two had 
incomplete responses to CaG chemotherapy. The remaining 
Table II. Patient characteristics.
 Historical control study 
 --------------------------------------------------------------------------------------------------
Characteristic The present study (n=33) Total (n=76) CaG (n=37) M-VAC (n=39) P-value
Age, years     0.31
  Median 70 67 67 66 
  Range 46-78 52-78 52-78 53-77 
Sex, n (%)     0.23
  Male 23 (70) 61 (90) 30 (88) 31 (91) 
  Female 10 (30) 7 (10) 4 (12) 3 (9) 
Clinical T stage, n (%)     0.14
  cT2 17 (52) 24 (32) 16 (43) 8 (21) 
  cT3 14 (42) 45 (59) 15 (41) 30 (77) 
  cT4 2 (6) 7 (9) 6 (16) 1 (3) 
The first therapy, n (%)     0.0003
  M-VAC 7 (21) 39 (51) - 39 (100) 
  CaG 21 (64) 37 (49) 37 (100) - 
  Surgery 1 (3) 0 0 0 
  Radiation 4 (12) 0 0 0 
The second therapy, n (%) 28 (85)    0.25
  M-VAC surgery 5 (15) 28 (37) - 28 (72) -
  M-VAC radiation 2 (6) 11 (14) - 11 (28) 
  CaG surgery 19 (58) 30 (39) 30 (81) - 
  CaG radiation 2 (6) 7 (10) 7 (19) - 
M-VAC, methotrexate, vinblastine, doxorubicin plus cisplatin; M-VAC, methotrexate, vinblastine, doxorubicin plus cisplatin; CaG, carboplatin 
plus gemcitabine.
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negative PS patient was a non-responder. PPACaG and NPACaG 
were 88.9% (16/18) and 33.3% (1/3). Therefore, in this prospec-
tive study, the total predictive accuracy of a combination of 
PPAM-VAC and PPACaG with NPACaG was 82.1% (23/28). On the 
other hand, among of the test cases in the historical control 
study, the PPAM-VAC and NPAM-VAC, and PPACaG and NPACaG 
of test cases were 87.5% (14/16) and 100% (5/5), and 100% 
(10/10) and 88.9% (8/9), respectively (2-4). Therefore, the 
predictive accuracy of a combination of PPAM-VAC, PPACaG, 
NPAM-VAC, and NPACaG was 92.5% (37/40) (2-4). Based on 
these results, the predictive accuracies of a combination of 
PPAM-VAC, PPACaG, NPAM-VAC, and NPACaG in the prospective 
and historical control study were 82.1% (23/28) and 92.5% 
(37/40), respectively, which were not statistically significant 
(P=0.25; Table III).
The proportion of patients with positive PS for each 
M-VAC and CaG was 45.5% (15/33) and 57.6% (19/33), respec-
tively. Moreover, 75.8% (25/33) of patients could be expected 
to respond to at least one of these two regimens by applying 
our two prediction systems (Fig. 2). In contrast, among of our 
historical control study, 64.1% (25/39) cases using the M-VAC 
scoring system and 51.4% (19/37) using the CaG scoring 
system were positive PS cases (2-4). Therefore, combining 
the 76 cases in historical control study, the average propor-
tion of patients predicted to be responders was 57.9% (44/76) 
(75.8 vs. 57.9%; P=0.087; Table II).
The clinical responses to M-VAC and CaG in this prospec-
tive study were 85.7% (6/7) and 88.9% (16/18). Therefore, the 
clinical response to M-VAC and CaG was 88.0% (22/25). On 
the other hand, in the historical controls, M-VAC and CaG 
clinical responders were 59.0% (23/39) and 54.1% (20/37), 
respectively. Therefore, the average of clinical responses of 
M-VAC and CaG was 56.6% (43/76). Consequently, it was 
found that the clinical response of the cases who received NAC 
in the prospective study was significantly higher than that of 
the historical controls (88.0 vs. 56.6%; P=0.0041; Table II).
Histological response to NAC. The number of the surgical 
cases in the prospective and in the historical control study 
in the neoadjuvant setting were 85.7% (24/28) and 75.0% 
(57/76), respectively (P=0.296; Table II). In the former, 13 of 
24 patients who received surgery were downstaged, eight had 
stable disease, and three were upgraded. Especially pT0 case 
was only one case (1/24) in this study. None of three negative 
PS cases accomplished downstaged. Among the four positive 
PS cases in which surgery was unable to be performed, two 
had disease progression (M-VAC, 1; CaG, 1), one was due 
to interstitial pneumonia (CaG, 1) and one refused surgery 
(M-VAC, 1) (Fig. 1). In the historical control group, 36 of 
57 cases were downstaged, 18 had stable disease, and 3 were 
upgraded. Moreover, pT0 cases were eight cases (8/57) in 
historical controls. No significant difference was detected in 
the proportion both of downstaged and pT0 cases between our 
prospective study (54.2% (13/24); 4.2% (1/24)) and historical 
control study [63.2% (36/57); 14.0% (8/57)] (54.2 vs. 63.2%; 
P=0.466; 4.2 vs. 14.0%; P=0.268; Table II).
Overall survival. The median follow-up period of the 
33 patients in this prospective study was 40.0 months in the 
present cohort. During the follow-up period, nine patients 
died: Eight died of bladder cancer and one died of small cell 
lung cancer. Among eight death cases, four with positive PS 
and four with negative PS. The small cell lung cancer death 
case was positive PS. The overall survival between 25 cases in 
the positive PS group and eight cases in the negative PS group 
was longer in the positive PS group with significant difference 
(P=0.027; Fig. 3A). However, in the historical control study, 
there were no statistically significant between the positive and 
the negative PS group in terms of overall survival (P=0.096; 
Fig. 3A). The median overall survival of positive PS was 
not reached and that of negative PS group was 43.5 months 
in this prospective study (Fig. 3A). The overall survival 
of this prospective study was superior to that of historical 
Figure 2. Scatter plot of two PSs for each 33 patients. The horizontal rows represent M-VAC PS and the vertical columns represent CaG PS. Each case is plotted 
corresponded to M-VAC and CaG PSs. At least either M-VAC or CaG PS would be greater than zero; the cases plotted with blue represent positive PS cases, 
the cases plotted with red represent negative PS cases. M-VAC, methotrexate, vinblastine, doxorubicin plus cisplatin; CaG, carboplatin plus gemcitabine; PS, 
prediction score.
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control from 30 to 50 months but not statistically significant 
(P=0.299; Fig. 3B).
Discussion
The prediction systems for sensitivity to neoadjuvant M-VAC 
and CaG were established from genome-wide expression 
studies using microarray analyses (2-4). We hypothesized 
that more patients would be predicted to be responders to the 
NACs and actual respond to them unless the two prediction 
systems receive little interference each other. Therefore, 
this prospective study was designed to investigate whether 
the combination of two prediction scoring systems lead to 
increasing the number of responders to MIBC treatments. The 
proportions of predicted to be responder between the present 
cohort [75.8% (25/33)] and the historical control cohort 
Table III. Accuracy of predicted clinical response in NAC cases.
 The present Historical control study %
Clinical response study % (n=33) (n=76: M-VAC, 39; CaG, 37) Odds ratio 95% CI P-value
Accuracy of the prediction system 82.1 (23/28a) 92.5 (37/40b) 0.37 0.08 to 1.71 0.259
The rate of predicted to be responder 75.8 (25/33) 57.9 (44/76) 2.27 0.91 to 5.69 0.087
Clinical response rate of NAC cases 88.0 (22/25c) 56.6 (43/76) 5.63 1.55 to 20.42 0.0041d
The rate of surgery after NAC 85.7 (24/28) 75.0 (57/76) 2.00 0.62 to 6.50 0.296
The rate of downstaged (pT1≤) 54.2 (13/24) 63.2 (36/57) 0.69 0.26 to 1.81 0.466
The rate of pT0 4.2 (1/24) 14.0 (8/57) 0.27 0.03 to 2.26 0.268
Excluding a5 patients who declined NAC; b36 (M-VAC 18, CaG 18) learning cases; and c3 NAC cases with negative PSs. dP<0.01. NAC, 
neoadjuvant chemotherapy; CI, confidence intervals; M‑VAC, methotrexate, vinblastine, doxorubicin plus cisplatin.
Figure 3. Overall survival rate. (A) Comparison of positive and negative PS patients, and positive and negative PS of HC patients. (B) Comparison of this 
prospective study and the HC study. PS, prediction score; HC, historical control.
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[57.9% (44/76)] did not indicate the statistically significant 
differences (P=0.087). However, in this prospective study, 22 
of 25 (88.0%) patients achieved significant tumor shrinkage 
when treated with appropriate NAC based on the results of the 
prediction systems; this rate was significantly higher than that 
of single regimen treatment 56.6% (43/76); (88.0 vs. 56.6%; 
P=0.0041). These results suggest that each patient may have 
a different profile for sensitivity to M‑VAC and CaG, even 
in our prospective study as well as previous reports (10-13). 
The accuracies of predicting system between this prospective 
study and the historical controls were not statistically signifi-
cant. (82.1% (23/28) vs. 92.5% (37/40); P=0.259).
In terms of invasion to the patients, predicting system 
requires the patients only to receiving cold biopsy with histo-
pathologic examination. Therefore, it is good point that there 
would be minimal invasiveness to patients. Moreover, it does 
not influence several other prediction systems concerning 
prognostic factors (14,15).
We did not adopt a combination with gemcitabine plus 
cisplatin (GC) but a CaG regimen because carboplatin causes 
less damage than cisplatin in renal function, and because the 
non-coincidence of drugs between CaG and M-VAC groups 
would provide a greater chance for each patient to receive the 
most promising chemotherapy. Indeed, GC chemotherapy is 
the gold standard for advanced bladder cancer (16) and has 
been reported that GC NAC was comparable to M-VAC 
in terms of the pT0 rate in NAC setting (17-20). However, 
Dogliotti et al (21) reported in a randomized study comparing 
GC vs. CaG for advanced urothelial cancer that the GC group 
had a better prognosis, but there were no statistically signifi-
cant differences in overall survival. Other report suggested 
that CaG regimen can be considered a reasonable in the NAC 
setting in especially for cisplatin unfit case (22,23).
Several clinical reports showed that patients who achieve 
pT0 have a good prognosis; (24-26) however, in our prospec-
tive study, only a very small number of cases achieved free of 
residual disease (pT0) (only 1 case of the 33 cases received CaG 
NAC). Our previous results were reported that the incidence of 
pT0 cases was 6% in the M-VAC group and 15% in the CaG 
group (23). The reason could be that our study showed such a 
low pT0, because no patient had undergone TUR-BT before 
NAC so as to investigate the chemo-sensitivity of each case. 
Interestingly, similar to our results, Scattoni et al (27) reported 
that the incidence of pT0 was 9% in patients who were treated 
with platinum-based chemotherapy without TUR-BT. In the 
SWOG-S8710 and JCOG0209 trials in which TUR-BT was 
performed for every case, the proportions of patients who did 
not receive chemotherapy and achieved pT0 were 11.7 and 
9.4%, respectively (24,28). Based on these results, we estimate 
that the effects of chemotherapy combined with TUR-BT 
would have not only an additive effect, but also a synergistic 
effect.
We analyzed the overall survivals of the patients between 
positive PS and negative PS, patients with positive PS showed 
significant longer overall survival than patients with negative 
PS (P=0.027). Among of the eight negative PS patients, the 
number of deaths in surgery and radiotherapy was two out of 
four cases during followed up period equally, the proportion 
of negative PS patients less received NAC and cystectomy 
than that of positive PS patients. Because each patient received 
several different treatments, the comparison with cohorts 
would not be accurate. But the patients with positive PS in 
prospective study were better prognosis than that of patients in 
retrospective study. There is possibility that the patients in this 
prospective study had the more opportunity to select regimens 
that could be expected to be effective than the patients in the 
retrospective study. The slightly better OS in the prospective 
study than retrospective study would suggest the allocating 
effect of our prediction systems. In the future, we would have 
to choose the alternative treatment instead of surgery or radia-
tion therapy to negative PS patients.
As for other limitations of our prospective study, when one 
regimen was performed for a predicted responder, the other 
regimen, regardless of the prediction result, was not used. 
Therefore, selection bias is present for NPAM-VAC and NPACaG. 
Moreover, possible explanations include that this small study 
be unable to adequately stratify patients. Especially, the 
numbers of negative PS patients were too small to calculate 
the accuracies and efficacies correctly. The tumor shrinkage 
cut-off rate was set at 60% because, in the M-VAC retrospec-
tive study, this shrinkage rate most clearly discriminated good 
from poor prognoses in terms of overall survival (data not 
published). Therefore, a shrinkage rate cut-off line of 60% was 
adopted in the CaG retrospective study (4). However, RECIST 
classification is widely used clinically as a method of evalu-
ating therapeutic effect. Though our prediction system is not 
able to apply to the RECIST criteria, we tried to check the 
coefficient between shrinking rates of two dimension of this 
study and RECIST criteria. The result of Pearson's correlation 
coefficient this prospective test and the historical control test 
was relatively high (r=0.691).
This is the first report to suggest that the combination 
of predicting systems for the response to M-VAC and 
CaG increases clinical efficacy by allowing clinicians 
to prospectively select the optimal regimen based on the 
result of prediction system for each patient. In the future, it 
should be necessary to investigate of this study in a larger 
group to adequately stratify patients and to make statistical 
accuracy. Moreover, future prospective studies of TUR-BT 
should be performed incorporating the combination of 
predicting systems for the response to M-VAC and CaG and 
to examine the effect on survival as a function of chemo-
therapy regimen.
In conclusion, to the best of our knowledge this study repre-
sents the first prospective study predicting chemo‑sensitivity 
for MIBC. These results indicate that the described prediction 
system can increase treatment efficacy for MIBC patients with 
minimum invasiveness by proposing the optimal regimen. 
This ability is clinically applicable as ‘Precision Medicine’; 
however, larger prospective trials are required.
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